GeNeuro announced that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update. The ProTEct-MS trial has been conducted at the Center for Neurology of ASC, the large MS center in Sweden.

The one-year Phase 2 trial has enrolled 40 patients whose disability progresses without relapses as they have previously received chronic anti-CD20-Ab therapy with rituximab. Results are expected to document the safety and tolerability of temelimab following higher doses (up to 54mg/kg/month), as well as efficacy based on the latest biomarkers associated with disease progression. Despite the availability of effective treatments against acute inflammation and relapses, about 80% of MS patients suffer from the progression of their disability over time, which remains the key unmet medical need in MS.